Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 8/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.59 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318707 | 0.89 | HSD17B10 (0.65) | OPRL1OPRM1OPRK1OPRD1HSD17B10 | |
| SCHEMBL21634299 | 0.86 | HSD17B10 (0.62) | OPRL1OPRM1OPRK1OPRD1HSD17B10 | |
| SCHEMBL21634315 | 0.85 | HSD17B10 (0.60) | OPRL1OPRM1OPRK1OPRD1HSD17B10 | |
| SCHEMBL5329597 | 0.84 | OPRM1 (0.62) | OPRL1OPRM1OPRK1OPRD1HSD17B10 | |
| SCHEMBL13853705 | 0.83 | OPRK1 (0.58) | OPRL1OPRM1OPRK1OPRD1HSD17B10 | |
| SCHEMBL14543210 | 0.83 | HSD17B10 (0.60) | OPRL1OPRM1OPRK1OPRD1HSD17B10 | |
| SCHEMBL21688404 | 0.82 | OPRK1 (0.57) | OPRL1OPRM1OPRK1OPRD1HSD17B10 | |
| SCHEMBL5459394 | 0.82 | OPRM1 (0.57) | OPRL1OPRM1OPRK1OPRD1HSD17B10 | |
| SCHEMBL318858 | 0.80 | CCR5 (0.75) | OPRL1OPRM1OPRK1OPRD1HSD17B10 | |
| SCHEMBL4981531 | 0.80 | SLC6A9 (0.57) | OPRL1OPRM1OPRK1OPRD1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
| US-6919349-B2 | Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient | TORAY INDUSTRIES, INC. (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040087574-A1 | Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient | TORAY INDUSTRIES INC. (JP) | 2004-05-06 | — | — | US | disclosed |
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | TORAY INDUSTRIES, INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1329451-A1 | SPIRO COMPOUNDS AND ADHESION MOLECULE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-23 | — | — | EP | disclosed |
| EP-1323709-A1 | UREA DERIVATIVE AND ADHESIVE-MOLECULE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | ICAM1, VCAM1, EPCAM | OPRL1 2032/4885OPRM1 766/4885OPRK1 2621/4885 |
| US-20040087574-A1 | Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient | VCAM1, ICAM1, SELL | OPRL1 738/4885OPRM1 2044/4885OPRK1 1419/4885 |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | OPRL1 2021/4885OPRM1 3240/4885OPRK1 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.